A Phase I, Single-Center, Single-blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CAT-354 Following Subcutaneous Administration in Healthy Male and Female Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2012
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- 15 Mar 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 15 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.